Evidence map›Paper›PMID 41365640›Full record

ArticleImmunology2026

Variation in Microbiome Composition and Faecal Metabolites Are Associated With Differential Susceptibility to DSS-Induced Colitis.

Jessica M Till, Orion D Brock, Elyza A Do, Morgan J Engelhart, Robert W P Glowacki, Shaomin Hu, Ansel Hsiao, Ina Nemet, Philip P Ahern

Abstract read
In one paragraph

Article in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica M TillDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, USA.
Orion D BrockDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, USA.
Elyza A DoDepartment of Microbiology & Plant Pathology, University of California Riverside, Riverside, California, USA.ORCID 0000-0003-3264-8138
Morgan J EngelhartDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, USA.
Robert W P GlowackiDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, USA.
Shaomin HuDepartment of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Ansel HsiaoDepartment of Microbiology & Plant Pathology, University of California Riverside, Riverside, California, USA.
Ina NemetDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, USA.
Philip P AhernDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-2083-3224

Funding

The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Fabio Cominelli · 2015 to 2026
$15.6M
Vibrio cholerae antinitrosative stress defenses and gut microbiome interactionR01AI157106 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HSIAO, ANSEL, ZHU, JUN · 2020 to 2024
$4.0M
The role of a bifunctional mucinase in modulating personalized gut microbiota-Vibrio cholerae interactions during infectionR01AI178908 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ansel Hsiao, Jun Zhu · 2023 to 2026
$3.2M
Unraveling strain-level variation in the induction of anti-inflammatory responses in the intestineR01DK126772 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI AHERN, PHILIP PATRICK · 2021 to 2025
$2.4M
Defining the impact of interpersonal gut microbiota variation on oral cholera vaccine responsivenessR01AI181382 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Philip Patrick Ahern, Ansel Hsiao · 2024 to 2026
$2.3M
Gut-microbial metabolism of aromatic amino acids and cardiovascular diseaseR01HL160747 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI NEMET, INA · 2022 to 2025
$2.2M
Small molecule signaling in regulation of gut microbiota structure and colonization resistanceR35GM158026 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI HSIAO, ANSEL · 2025 to 2025
$2.1M
Cleveland Clinic FoundationDivision of Loan Repayment LRP0000016021Division of Loan Repayment LRP0000045724National Institute of Allergy and Infectious Diseases F31AI179030NHLBI NIH HHS R01 HL160747NIAID NIH HHS R01 AI157106NIAID NIH HHS R01 AI178908NIAID NIH HHS R01 AI181382NIDDK NIH HHS P30 DK097948NIDDK NIH HHS R01 DK126772NIGMS NIH HHS R35 GM158026NIGMS NIH HHS R35GM158026
6 · The paper itself

Abstract

Variation in microbiome composition is linked to differences in intestinal immune phenotypes and can be leveraged to identify microbiome-driven contributions to phenotypes of interest. Furthermore, such variation has been associated with differing inter-individual susceptibility to the development of inflammatory bowel disease (IBD), a chronic inflammatory disease of the gastrointestinal tract that is driven by dysfunctional immune-microbiome interactions. Here, we identified that differences in microbiome composition in C57BL/6 mice from two commonly used commercial vendors, Charles River (CR) and Jackson (JAX) Laboratories, were associated with variation in the intestinal immune phenotype, with CR mice having greater Th17 levels and faecal IgA. In turn, CR mice demonstrated enhanced susceptibility to the dextran sulfate sodium (DSS)-induced model of colitis compared to JAX mice. Co-housing studies revealed that CR mice could transmit enhanced susceptibility to colitis to JAX mice, implicating differences in microbiome composition as drivers of disease susceptibility. Faecal metabolomics studies using targeted mass spectrometry revealed several metabolites differentially enriched in colitis-susceptible and colitis-resistant mice. Correlation analysis uncovered metabolites that were both negatively and positively associated with colitis severity. Taken together, our study leveraged natural microbiome variation to identify gut microbial metabolites with the potential to predict the severity of IBD. Importantly, we further establish susceptible and non-susceptible murine microbial communities that represent a tractable system in which to further uncover microbiome contributions to IBD in the DSS-colitis model.

Indexed as

ColitisFecesGastrointestinal MicrobiomeAnimalsDextran SulfateDisease Models, AnimalDisease SusceptibilityFemaleImmunoglobulin AInflammatory Bowel DiseasesMaleMetabolomicsMiceMice, Inbred C57BLTh17 CellsDextran SulfateImmunoglobulin AinflammationmetabolomicsmicrobiomeT cell

Identifiers

PMID41365640
PMCPMC12952986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.